Saisei Ventures Invests in United Immunity, Co., Ltd., to Develop New Cancer Immune-Therapeutics Using Proprietary Immune Cell-Selective Delivery Technology
Saisei Ventures is pleased to announce a new investment in United Immunity, a biotechnology company developing proprietary tumor-associated-macrophage-selective nanoparticles.
Saisei Ventures Enters into Letters of Intent with Healios and will Launch a Special Opportunities Co-Investment Fund
Saisei Ventures is pleased to announce the signing of two letters of intent and will launch a new Special Opportunities co-investment fund.
Saisei Ventures is Selected as a Certified VC Fund by AMED to Catalyze the Japanese Drug Development Ecosystem
Saisei Ventures is one of nine VC firms accredited by AMED for funding as part of its Drug Discovery Venture Ecosystem Enhancement Project.
© 2023 Saisei Ventures